PD-L1 assessment in urothelial carcinoma: a practical approach

If you need an accessible version of this item, please submit a remediation request.
Date
2019-11
Language
American English
Embargo Lift Date
Committee Members
Degree
Degree Year
Department
Grantor
Journal Title
Journal ISSN
Volume Title
Found At
Society for Translational Medicine (STM)
Abstract

Five programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors are currently approved for treatment of locally advanced or metastatic urothelial carcinoma of the bladder and the upper urinary tract. Due to restrictions by the FDA and EMA first-line treatment with Atezolizumab and Pembrolizumab in platinum-ineligible patients requires immunohistochemical PD-L1 testing. In the second-line setting all drugs are approved without PD-L1 testing. Used PD-L1 assays in clinical trials include the 28-8 pharmDx (Nivolumab), the 22C3 pharmDx (Pembrolizumab), Ventana SP142 (Atezolizumab), and the Ventana PD-L1 SP263 assays (Durvalumab). Differences in antibodies, needed platforms and testing algorithms have raised questions about interchangeability and comparability among these assays and their diagnostic use. We provide a practical review about the current recommendations, used assays and algorithms of PD-L1 testing in urothelial carcinoma to help oncologists, urologists and pathologists to understand analytical features, differences in antibody assays, differences in scoring algorithms and comparability of various PD-L1 assays. We reviewed and summarized published studies from the last four years (2016–2019) on PD-L1 testing in bladder cancer and present a condensed practical guideline including pre-analytical, analytical and test-specific issues.

Description
item.page.description.tableofcontents
item.page.relation.haspart
Cite As
Eckstein, M., Cimadamore, A., Hartmann, A., Lopez-Beltran, A., Cheng, L., Scarpelli, M., ... & Gevaert, T. (2019). PD-L1 assessment in urothelial carcinoma: a practical approach. Annals of Translational Medicine, 7(22). 10.21037/atm.2019.10.24
ISSN
2305-5847
Publisher
Series/Report
Sponsorship
Major
Extent
Identifier
Relation
Journal
Annals of translational medicine
Source
PMC
Alternative Title
Type
Article
Number
Volume
Conference Dates
Conference Host
Conference Location
Conference Name
Conference Panel
Conference Secretariat Location
Version
This item is under embargo {{howLong}}